Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Palmitic acid: Protocol and QC Guide
2026-10-01
Palmitic acid (hexadecanoic acid, SKU N2456) provides a characterized saturated long-chain fatty acid for solvent-controlled studies of lipid metabolism, inflammation, insulin signaling, and protein palmitoylation. It should be prepared in ethanol or DMSO rather than added directly to aqueous systems, and freshly prepared solutions are preferred over long-term storage.
-
HotStart Universal 2X Green qPCR Master Mix Workflow
2026-09-30
Build a reproducible real-time PCR gene expression analysis workflow for fusion transcripts, pathway markers, and treatment-response studies. This guide shows how hot-start chemistry, Green I fluorescence, ROX normalization, and melt curve analysis can strengthen assay specificity without obscuring the limits of dye-based detection.
-
Cell lysis buffer for WB and IP in CAF Studies
2026-09-29
Use a non-denaturing extraction workflow to connect cancer-associated fibroblast signaling with Western blot, co-IP, and pathway validation. This guide shows how K1123 supports protein degradation prevention while preserving the protein associations needed to investigate ANGPTL4–IQGAP1 signaling and prostate cancer chemoresistance.
-
Q-VD-OPh for Mitochondrial Apoptosis Workflows
2026-09-29
Q-VD-OPh helps separate caspase-dependent execution from earlier mitochondrial events in apoptosis and super-resolution mRNA imaging. This workflow-focused guide covers dosing logic, cryopreservation support, imaging controls, and troubleshooting for more interpretable cell-death assays.
-
Spleen-Targeted LNPs for Anticancer mRNA Vaccines
2026-09-28
A 2025 study shows that changing ionizable and helper lipid composition can redirect intravenous lipid nanoparticles (LNPs) toward splenic antigen-presenting cells. Optimized CL15H6 LNPs delivered ovalbumin mRNA, reduced tumor growth by approximately 75% in a mouse model, and maintained a favorable acute and repeat-dose safety profile.
-
Tamsulosin and Prevention of Postoperative Urinary Retention
2026-09-28
This systematic review and meta-analysis found that perioperative tamsulosin was associated with a lower risk of postoperative urinary retention (POUR) across randomized trials, while also increasing maximum urinary flow rate. The findings support considering tamsulosin as a preventive option, but variation in trial protocols and the lack of a single optimal regimen limit how directly the pooled result can guide individual surgical pathways.
-
Bismuth Subsalicylate in Cell Assay Workflows
2026-09-27
This practical guide explains how to evaluate Bismuth Subsalicylate (SKU A8382) in viability, proliferation, and apoptosis workflows without mistaking compound-handling effects for biological results. It combines product specifications with literature-supported annexin V principles and highlights controls, formulation limits, and vendor-selection considerations.
-
Anlotinib Hydrochloride: Reading Angiogenesis Assays
2026-09-26
Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor for studying angiogenic signaling. This guide focuses on a practical question often missed in mechanism summaries: how to distinguish receptor-pathway suppression from general cell stress when interpreting endothelial assays.
-
Anlotinib Hydrochloride in Angiogenesis Assays
2026-09-25
Use Anlotinib hydrochloride to connect VEGFR2, PDGFRβ, and FGFR1 inhibition with practical endothelial migration, tube-formation, and ERK readouts. A rare-tumor case report adds translational context, while the workflows below keep cell-based findings distinct from clinical evidence.
-
Doxorubicin Hydrochloride: Applied Research Workflows
2026-09-25
Turn Adriamycin HCl into a reproducible tool for cancer-cell response studies and cardiac injury models, with practical guidance on dose finding, assay selection, and troubleshooting. A recent ATF4–H₂S study adds a mechanistic framework for testing oxidative stress and cardioprotection alongside doxorubicin exposure.
-
Ruxolitinib Triggers ATC Cell Death Through DRP1
2026-09-24
The study links JAK1/2–STAT3 inhibition by ruxolitinib to reduced DRP1 transcription, impaired mitochondrial fission, and caspase-dependent apoptosis and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma models. Its mechanistic findings identify DRP1 as a connection between STAT3 signaling and mitochondrial dynamics, while supporting further preclinical investigation rather than establishing clinical efficacy in patients.
-
Fosinopril Sodium: From ACE Mechanism to Translation
2026-09-24
A translational guide to using Fosinopril sodium in hypertension and cardiovascular research, connecting ACE inhibition and prodrug pharmacology with experimental design, evidence boundaries, and clinical context.
-
Anlotinib Hydrochloride: Translating Angiogenesis Biology
2026-09-24
Anlotinib hydrochloride offers translational researchers a way to interrogate how VEGFR2, PDGFRβ, and FGFR1 converge on ERK signaling and angiogenic behavior. This article connects target-level potency with functional assay design, considers what a reported desmoplastic small round cell tumor case can—and cannot—tell us, and outlines practical steps for building more informative cancer research models.
-
Moesin as a Biomarker of Endothelial Injury in Sepsis
2026-09-23
The reference study identifies circulating moesin as a candidate marker of endothelial injury and sepsis severity, linking higher levels with SOFA scores, procalcitonin, pulmonary edema, and lung damage. Its combination of patient observations, mouse models, and endothelial-cell experiments also suggests that moesin contributes functionally through ROCK1/MLC and NF-κB signaling rather than serving only as a passive indicator.
-
Apigenin Workflows for HDAC and Neuroprotection
2026-09-22
Apigenin supports two complementary bench strategies: malignant mesothelioma cell growth inhibition through HDAC-linked apoptosis, and neuroprotection studies integrating oxidative stress, mitochondrial injury, and inflammation. This practical guide connects dose selection, assay controls, workflow design, and troubleshooting without overstating preclinical findings.